No Association between SARS-CoV-2 Infection and the Polymorphism of the Toll-like Receptor 7 (TLR7) Gene in Female Population

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a single-stranded RNA virus. Toll-like receptor 7 (TLR7) recognizes single-stranded RNA viruses. The TLR7 gene plays a critical role in the human innate and adaptive immune response to SARS-CoV-2 infections. Genetic factors probably affect SARS-CoV-2 infection susceptibility. In the current study, our aim was to search for genetic variations associated with COVID-19 patients in the TLR7 gene of a Korean population. We designed five gene-specific primers to cover the coding region of the human TLR7 gene. Using amplicon sequencing, we screened the genetic polymorphisms in the coding region of the TLR7 gene in COVID-19 patients and healthy controls. The genotype frequencies, allele frequencies, and Hardy–Weinberg equilibrium (HWE) were examined. We identified a low-frequency synonymous single nucleotide polymorphism (SNP) (rs864058) in the coding region of the TLR7 gene. There were no significant differences in the genotype or allele frequencies of the TLR7 rs864058 polymorphism between COVID-19 female patients and healthy controls (p = 1.0). In conclusion, TLR7 (rs864058) polymorphism is low frequency in Korean populations and is not associated with SARS-CoV-2 infection.

[1]  Raed S Ismail,et al.  Association between genetic polymorphism, severity, and treatment response among COVID-19 infected Egyptian patients , 2023, Frontiers in Pharmacology.

[2]  K. Zaher,et al.  Gender Differences in Response to COVID-19 Infection and Vaccination , 2023, Biomedicines.

[3]  M. Lotfy,et al.  Impact of Toll-Like Receptor 2 and 9 Gene Polymorphisms on COVID-19: Susceptibility, Severity, and Thrombosis , 2023, Journal of inflammation research.

[4]  M. Litvinova,et al.  TLRs Gene Polymorphisms Associated with Pneumonia before and during COVID-19 Pandemic , 2022, Diagnostics.

[5]  Ming-Hui Yang,et al.  Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments , 2022, Frontiers in Pharmacology.

[6]  M. Sohn,et al.  How to cope with emerging viral diseases: lessons from South Korea's strategy for COVID-19, and collateral damage to cardiometabolic health , 2022, The Lancet Regional Health - Western Pacific.

[7]  A. Hoischen,et al.  Clinical implications of host genetic variation and susceptibility to severe or critical COVID-19 , 2022, Genome medicine.

[8]  A. Mącznik,et al.  Risk Factors for Contracting COVID-19 and Changes in Menstrual and Sleep Cycles in Japanese Female Athletes during the COVID-19 Pandemic , 2022, Sports.

[9]  E. Quiros-Roldan,et al.  Omicron BA.2 Lineage, the “Stealth” Variant: Is It Truly a Silent Epidemic? A Literature Review , 2022, International journal of molecular sciences.

[10]  Ziyuan Gao,et al.  Toll-Like Receptor Signaling in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Innate Immune Responses and the Potential Application Value of Toll-Like Receptor Immunomodulators in Patients With Coronavirus Disease 2019 , 2022, Frontiers in Microbiology.

[11]  S. Soliman,et al.  COVID-19 susceptibility, severity, clinical outcome and Toll-like receptor (7) mRNA expression driven by TLR7 gene polymorphism (rs3853839) in middle-aged individuals without previous comorbidities , 2022, Gene Reports.

[12]  K. Dua,et al.  Toll-like receptors, innate immune system, and lung diseases: a vital trilateral association , 2022, EXCLI journal.

[13]  L. Kristensen,et al.  TLR2 and TLR7 mediate distinct immunopathological and antiviral plasmacytoid dendritic cell responses to SARS‐CoV‐2 infection , 2022, The EMBO journal.

[14]  Ahmed El-Mesery,et al.  Prognostic impact of toll-like receptors gene polymorphism on outcome of COVID-19 pneumonia: A case-control study , 2022, Clinical Immunology.

[15]  M. Mondelli,et al.  Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients , 2021, Genes and immunity.

[16]  Rahul Singh,et al.  Role of toll-like receptor 7/8 pathways in regulation of interferon response and inflammatory mediators during SARS-CoV2 infection and potential therapeutic options , 2021, Biomedicine & Pharmacotherapy.

[17]  V. Vasiliou,et al.  COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy , 2021, Human genomics.

[18]  C. Jonsson,et al.  TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines , 2021, Nature Immunology.

[19]  J. Schuurs-Hoeijmakers,et al.  Genetic Screening for TLR7 Variants in Young and Previously Healthy Men With Severe COVID-19 , 2021, Frontiers in Immunology.

[20]  B. Jeong,et al.  The first association study of single-nucleotide polymorphisms (SNPs) of the IFITM1 gene with influenza H1N1 2009 pandemic virus infection , 2021, Molecular & Cellular Toxicology.

[21]  N. Rezaei,et al.  Role of Toll‐like receptors in the pathogenesis of COVID‐19 , 2021, Journal of medical virology.

[22]  B. Jeong,et al.  Strong Correlation between the Case Fatality Rate of COVID-19 and the rs6598045 Single Nucleotide Polymorphism (SNP) of the Interferon-Induced Transmembrane Protein 3 (IFITM3) Gene at the Population-Level , 2020, Genes.

[23]  H. Peckham,et al.  Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission , 2020, Nature Communications.

[24]  B. Jeong,et al.  Ethnic variation in risk genotypes based on single nucleotide polymorphisms (SNPs) of the interferon-inducible transmembrane 3 (IFITM3) gene, a susceptibility factor for pandemic 2009 H1N1 influenza A virus , 2020, Immunogenetics.

[25]  B. Jeong,et al.  Genetic association between the rs12252 SNP of the interferon-induced transmembrane protein gene and influenza A virus infection in the Korean population , 2020, Molecular & cellular toxicology.

[26]  B. Jeong,et al.  Genetic association between the rs12252 SNP of the interferon-induced transmembrane protein gene and influenza A virus infection in the Korean population , 2020, Molecular & Cellular Toxicology.

[27]  Lin Qiu,et al.  Pregnant women with COVID-19 and risk of adverse birth outcomes and maternal-fetal vertical transmission: a population-based cohort study in Wuhan, China , 2020, BMC Medicine.

[28]  M. Woodward,et al.  Obesity as a risk factor for COVID‐19 mortality in women and men in the UK biobank: Comparisons with influenza/pneumonia and coronary heart disease , 2020, Diabetes, obesity & metabolism.

[29]  J. Schuurs-Hoeijmakers,et al.  Presence of Genetic Variants Among Young Men With Severe COVID-19. , 2020, JAMA.

[30]  Shaoying Huang,et al.  The cytokine storm and COVID‐19 , 2020, Journal of medical virology.

[31]  A. Javed,et al.  SARS-CoV-2 host diversity: An update of natural infections and experimental evidence , 2020, Journal of Microbiology, Immunology and Infection.

[32]  D. Ragab,et al.  The COVID-19 Cytokine Storm; What We Know So Far , 2020, Frontiers in Immunology.

[33]  Michael Berk,et al.  Genetic gateways to COVID‐19 infection: Implications for risk, severity, and outcomes , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  W. Ko,et al.  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges , 2020, International Journal of Antimicrobial Agents.

[35]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[36]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[37]  B. Jeong,et al.  Strong association of regulatory single nucleotide polymorphisms (SNPs) of the IFITM3 gene with influenza H1N1 2009 pandemic virus infection , 2019, Cellular & Molecular Immunology.

[38]  C. Petes,et al.  The Toll for Trafficking: Toll-Like Receptor 7 Delivery to the Endosome , 2017, Front. Immunol..

[39]  Klaudia Walter,et al.  The impact of rare and low-frequency genetic variants in common disease , 2017, Genome Biology.

[40]  Taro Kawai,et al.  Toll-Like Receptor Signaling Pathways , 2014, Front. Immunol..

[41]  A. Andiappan,et al.  Toll-like receptor gene polymorphisms are associated with allergic rhinitis: a case control study , 2012, BMC Medical Genetics.

[42]  V. Pankratz,et al.  Multigenic control of measles vaccine immunity mediated by polymorphisms in measles receptor, innate pathway, and cytokine genes. , 2012, Vaccine.

[43]  P. Sly,et al.  Toll-like receptor 7 function is reduced in adolescents with asthma , 2009, European Respiratory Journal.

[44]  Peter Kraft,et al.  Toll-like Receptor Signaling Pathway Variants and Prostate Cancer Mortality , 2009, Cancer Epidemiology Biomarkers & Prevention.

[45]  Y. Yun,et al.  Upregulation of TLR7 and TLR3 gene expression in the lung of respiratory syncytial virus infected mice. , 2009, Wei sheng wu xue bao = Acta microbiologica Sinica.

[46]  M. Nyegaard,et al.  Association analysis identifies TLR7 and TLR8 as novel risk genes in asthma and related disorders , 2008, Thorax.

[47]  T. Hawn,et al.  Toll-like receptor polymorphisms and susceptibility to human disease. , 2008, Clinical science.

[48]  S. Akira,et al.  Pathogen Recognition and Innate Immunity , 2006, Cell.

[49]  Zhibin Hu,et al.  Polymorphisms of TLR7 and TLR8 associated with risk of asthma and asthma-related phenotypes in a southeastern Chinese Han population , 2009 .